Nuvalent, Inc.NUVLNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

13 analysts·Moderate coverage

100%

Rating Distribution

Strong Buy

00%

Buy

13100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 29% higher.

Bear Case

$105.00

+2%

Consensus

$133.09

+29%

Bull Case

$155.00

+51%

Price Range13 analysts

Low

Consensus

High

$105.00

$155.00

Current Target

Current Price

$102.89

Upside to Target

$30.20

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-5.77(13 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+609.35%

EPS—

FY2028

Rev+163.48%

EPS—

FY2029

Rev+62.13%

EPS—

Earnings Surprises

Beat rate:17%(2/12 quarters)

Avg surprise:-7.3%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 24, 2025Truist Financial

Nuvalent initiated with a Buy at Truist

Target:$140.00

+32.2%from $105.88

Nov 17, 2025Barclays

Nuvalent price target raised to $152 from $112 at Barclays

Target:$152.00

+40.7%from $108.00

Nov 17, 2025Leerink Partners

Nuvalent price target raised to $149 from $140 at Leerink

Target:$149.00

+34.8%from $110.56

Nov 17, 2025H.C. Wainwright

Nuvalent price target raised to $155 from $130 at H.C. Wainwright

Target:$155.00

+40.1%from $110.60

Nov 12, 2025Canaccord Genuity

Canaccord starts 'best-in-class' Nuvalent with Buy rating

Target:$126.00

+31.0%from $96.16

Oct 31, 2025Goldman Sachs

Nuvalent price target raised to $120 from $105 at Goldman Sachs

Target:$120.00

+22.2%from $98.17

Oct 31, 2025UBS

Nuvalent (NUVL) PT Raised to $132 at UBS

Target:$132.00

+34.5%from $98.17

Oct 27, 2025Piper Sandler

Nuvalent price target raised to $128 from $112 at Piper Sandler

Target:$128.00

+37.1%from $93.39

Oct 15, 2025Cantor Fitzgerald

Nuvalent initiated with an Overweight at Cantor Fitzgerald

Target:$135.00

+51.1%from $89.35

Sep 3, 2025Guggenheim

Nuvalent assumed with a Buy at Guggenheim

Target:$122.00

+53.4%from $79.54

Sep 2, 2025Raymond James

Nuvalent initiated with an Outperform at Raymond James

Target:$105.00

+36.5%from $76.90

Jun 24, 2025H.C. Wainwright

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

Target:$130.00

+69.1%from $76.88

Nov 13, 2024BMO Capital

Nuvalent (NUVL) PT Raised to $134 at BMO Capital

Target:$134.00

+91.5%from $69.99

Oct 24, 2024UBS

UBS Starts Nuvalent (NUVL) at Neutral

Target:$100.00

+6.7%from $93.71

Sep 16, 2024Guggenheim

Nuvalent price target raised to $105 from $99 at Guggenheim

Target:$105.00

-4.8%from $110.25

Sep 16, 2024Stifel Nicolaus

Nuvalent (NUVL) PT Raised to $135 at Stifel

Target:$135.00

+54.4%from $87.45

Sep 16, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Nuvalent (NUVL)

Target:$100.00

+14.4%from $87.45

Jul 10, 2024Stifel Nicolaus

Nuvalent price target raised to $115 from $103 at Stifel

Target:$115.00

+56.2%from $73.63

Apr 17, 2024Jefferies

Jefferies Starts Nuvalent (NUVL) at Buy, 'Precisely Targeted Oncology Aiming for Firstline Treatment'

Target:$97.00

+49.8%from $64.75

Apr 1, 2024Leerink Partners

Nuvalent upgraded to Outperform from Market Perform at Leerink

Target:$110.00

+46.5%from $75.09

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance